Hana ʻo Serosurveillance i ka helu ʻana i ka laha o nā antibodies i loko o kahi heluna e kūʻē i kahi pathogen.Kōkua ia i ke ana ʻana i ka pale ʻana o ka heluna kanaka ma hope o ka maʻi a i ʻole ka hoʻopaʻa ʻana a loaʻa iā ia ka pono maʻi epidemiological i ke ana ʻana i nā pilikia o ka hoʻouna ʻana a me nā pae palekana o ka lehulehu.I ka maʻi maʻi coronavirus 2019 (COVID-19) i kēia manawa, ua hana koʻikoʻi ka serosurvey i ka nānā ʻana i ke kiʻekiʻe maoli o ka maʻi maʻi maʻi maʻi ʻehaʻeha coronavirus 2 (SARS-CoV-2) i nā lāhui like ʻole.Ua kōkua pū kekahi i ka hoʻokumu ʻana i nā hōʻailona epidemiologic, e laʻa, ka ratio fatality maʻi (IFR).
Ma ka hopena o 2020, ua paʻi ʻia he 400 serosurveys.Hoʻokumu ʻia kēia mau haʻawina i nā ʻano immunoassays ʻē aʻe i hoʻolālā ʻia e nānā i nā antibodies e kūʻē iā SARS-CoV-2, ka mea nui e kuhikuhi ana i nā mea āpau a i ʻole ʻāpana o ka spike (S) a me ka nucleocapsid (N) protein o SARS-CoV-2.I ka hanana maʻi maʻi COVID-19 i kēia manawa, ua kū mai nā nalu maʻi maʻi ma nā wahi like ʻole o ka honua, e hoʻopilikia ana i kahi hui like ʻole o ka heluna kanaka i kahi manawa i hāʻawi ʻia.Ua hoʻohālikelike kēia ʻano hanana i ka serosurveillance SARS-CoV-2 ma muli o kahi ʻāina immunological heterogeneous.
Ua ʻike ka poʻe ʻepekema ʻo ka anti-SARS-CoV-2 antibody pae i ka pohō ma hope o ka manawa convalescent.Hoʻonui kēia mau hanana i nā hopena maikaʻi ʻole e ka immunoassays.Hiki i kēia mau mea hoʻopunipuni ke hoʻohaʻahaʻa pono i ka paʻakikī o ka maʻi maoli ke ʻike ʻole ʻia a hoʻoponopono koke ʻia.Hoʻohui ʻia, ʻike ʻia nā kinetics antibody post-infection e like me ka paʻakikī o ka maʻi - ʻoi aku ka nui o ka maʻi COVID-19 e hoʻonui i ka piʻi nui o ka pae o nā antibodies i ka hoʻohālikelike ʻana i nā maʻi ʻeha a i ʻole asymptomatic.
Ua hōʻike ʻia kekahi mau haʻawina i nā kinetics antibody no ʻeono mahina ma hope o ka maʻi.Ua ʻike ʻia kēia mau haʻawina ʻo ka hapa nui o nā poʻe i nā kaiāulu i loaʻa i ka maʻi SARS-CoV-2 i hōʻike i nā maʻi maʻalahi a i ʻole asymptomatic.Manaʻo ka poʻe noiʻi he mea nui ia e helu i ka hoʻololi ʻana i nā pae antibodies, me ka hoʻohana ʻana i nā immunoassays i loaʻa, ma ka laulā ākea o ka nui o ka maʻi.Ua noʻonoʻo ʻia ka makahiki ma ke ʻano he mea nui i kēia mau haʻawina.
Ma kahi noiʻi hou, ua helu nā kānaka ʻepekema i nā pae anti-SARS-CoV-2 antibody a hiki i 9 mau mahina ma hope o ka maʻi, a paʻi i kā lākou ʻike mamedRxiv* kikowaena paʻi mua.Ma ka noiʻi o kēia manawa, ua kiʻi ʻia kahi cohort o nā poʻe seropositive ma o nā serosurveys i hana ʻia ma Geneva, Switzerland.Ua hoʻohana nā mea noiʻi i ʻekolu immunoassays like ʻole, ʻo ia hoʻi, semiquantitative anti-S1 ELISA e ʻike ana i ka IgG (i kapa ʻia ʻo EI), ka quantitative Elecsys anti-RBD (i kapa ʻia ʻo Roche-S) a me semiquantitative Elecsys anti-N (i kapa ʻia ʻo Roche- N).Hāʻawi ka noiʻi i kēia manawa i kahi ʻike koʻikoʻi i nā haʻawina serologic e pili ana i ka heluna kanaka a hōʻike i ka paʻakikī o ka ʻāina immune ma muli o ka hui ʻana o nā maʻi hou a me nā maʻi COVID-19, a me ka hoʻopaʻa ʻana.
Ua hōʻike ʻia ka haʻawina e noʻonoʻo ʻia ana i ka poʻe i hoʻopaʻa i ka COVID-19 me nā hōʻailona haʻahaʻa a i ʻole asymptomatic, i hōʻike i ka hele ʻana o nā antibodies.Kuhi ʻia kēia mau antibodies i ka nucleocapsid (N) a i ʻole ka spike (S) protein o ka SARS-CoV-2 a ua ʻike ʻia e hoʻomau ʻia ma kahi o 8 mau mahina ma hope o ka maʻi.Eia naʻe, hilinaʻi nui ko lākou ʻike ʻana i ke koho o ka immunoassay.Ua ʻike nā mea noiʻi ʻo nā ana mua o nā antibodies, i lawe ʻia mai nā poʻe i komo i loko o ʻehā a me ka hapa mahina o COVID-19, ua kūlike i nā ʻano ʻekolu o nā immunoassays i hoʻohana ʻia i kēia noiʻi.Eia naʻe, ma hope o nā mahina ʻehā mua, a hiki i ʻewalu mau mahina ma hope o ka maʻi maʻi, ua ʻokoʻa nā hopena ma waena o nā assays.
Ua hōʻike ʻia kēia noiʻi ma ka hihia o ka EI IgG assay, hoʻokahi o ʻehā mau mea komo i sero-reverted.Eia nō naʻe, no nā immunoassays ʻē aʻe, e like me ka Roche anti-N a me ka anti-RBD total Ig hoʻāʻo, he liʻiliʻi wale nō a ʻaʻohe sero-reversions i ʻike ʻia no ka laʻana like.ʻO nā poʻe i komo pū me nā maʻi maʻi maʻi, i manaʻo ʻia ma mua e loaʻa i nā pane kūlohelohe ʻoi aku ka ikaika, ua hōʻike i ka naʻau i ka wā e hoʻohana ana i nā hōʻike anti-RBD a me anti-N total Ig Roche.Ua hoʻomau ʻia nā assays ʻelua ma mua o 8 mau mahina ma hope o ka maʻi.No laila, ua hōʻike ʻia kēia mau hopena ua kūpono nā Roche immunoassays e koho i ka seroprevalence ma hope o ka manawa lōʻihi ma hope o ka maʻi mua.
Ma hope iho, me ka hoʻohana ʻana i nā loiloi simulation, ua hoʻoholo nā mea noiʻi me ka ʻole o ke ʻano helu helu pololei, ʻoi aku ka maikaʻi, me ka noʻonoʻo ʻana i ka ʻike ʻana o ka manawa, ʻaʻole pololei nā noiʻi seroprevalence.E alakaʻi ana kēia i ka manaʻo haʻahaʻa o ka helu maoli o nā maʻi kumulative i loko o kahi heluna.Ua hōʻike ʻia kēia haʻawina immunoassay i ke ʻano o nā ʻokoʻa o nā helu seropositivity ma waena o nā hoʻokolohua i loaʻa i nā mea kūʻai.
Pono e hoʻomaopopo he nui nā palena o kēia haʻawina.No ka laʻana, ʻokoʻa ka reagent i hoʻohana ʻia i ka hoʻāʻo ʻana o EI no ka papa kuhikuhi (hoʻāʻo mua a i ʻole 1st) a me ka hahai ʻana (2nd ho'āʻo no nā moho like) i loko o kahi manawa kikoʻī.ʻO kekahi palena ʻē aʻe o kēia noiʻi ʻana ʻaʻole i komo nā cohorts i nā keiki.I kēia lā, ʻaʻohe hōʻike o ka lōʻihi antibody dynamics i nā keiki i kākau ʻia.
Ka manawa hoʻouna: Mar-24-2021